Burcon NutraScience Corporation

Burcon reported Q1 revenue of $1.3 million, up 54% quarter-over-quarter and more than threefold versus the prior-year quarter. Operating loss decreased 7% quarter-over-quarter. Management announced a convertible debenture financing for gross proceeds of up to $8.1 million, expected to fund growth investments in labor, inventory, production capability, efficiency, working capital, and some debt retirement. Looking ahead, management said it expects double-digit revenue by the end of the calendar year and to become cash flow positive during the calendar year.

Kip Underwood framed the quarter around three themes: a strong protein market, execution of the operating plan, and continued investment for future growth. He emphasized that Burcon’s “unmatched purity” technology is commercially relevant across multiple products and that customer validation is showing up through repeat purchases. His tone was upbeat and confident, but he repeatedly stressed that the company still has to keep producing and selling day by day to convert the opportunity into results.

Alex Varty highlighted that Q1 revenue of $1.3 million grew 54% sequentially and more than threefold year over year, and that operating loss improved 7% quarter-over-quarter. He said the company has grown revenue sequentially every quarter since launching operations at Galesburg while keeping spending focused on production. On capital allocation, he said the up to $8.1 million convertible debenture is intended for growth investments, future capacity planning, efficiency improvements, working capital, and retiring certain debt obligations.

Analysts focused on the conversion of the 40 active buying customers, the sales funnel, and where repeat orders stand versus initial testing. Management said the customer base is diverse across food types, customer sizes, and products, with repeat purchase being the best proof that the technology and facility are delivering consistently. Questions on the financing were answered with a reminder that proceeds are for growth and that the close is expected shortly after the September 16 annual meeting, likely in late September or early October. On GLP-1 exposure, management said this is still “the first inning” and that North America remains the main focus.